Irinotecan plus cisplatin combination against metastatic gastric cancer: Phase II study

Medical Oncology

Volumn 22, Issue 2, 2005, Pages 153-160

  Altinbas, Mustafa ^a,c   Er, Ozlem ^a   Ozkan, Metin ^a   Solak, Yusuf ^a   Coskun, H Senol ^a   Kucuk, Can ^b   Gursoy, Sebnem ^c  

^a Medical Oncology ^*  (Turkey)

^b General Surgery

^c ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Chemotherapy; Cisplatin; CPT 11; Metastatic gastric cancer

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFECTION; KIDNEY DISEASE; LIVER DISEASE; MALE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 22344456355     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:22:2:153     Document Type: Article

References (30)

1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiology 2003;56:1-9.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:3-64.
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
4. Glimelius B, et al. Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168.
5. Moertel CG, et al. A phase II study of combined 5-fluoruracil, doxorubicin and cisplatin in the treatment of advanced gastrointestinal adenocarcinoma. J Clin Oncol 1986;4:1053-1057.
6. Kim NK, et al. A phase III randomized study of 5-fluoruracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-3818.
7. Ohtsu A, et al. Phase II study of protacted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 1994;30A:2091-2093.
8. Wall ME, et al. Plant antitumor agents. The isolation and structure of campthotecin, a novel alkaloidal leukemia and tumor inhibitor from Campthotheca acuminata. J Am Chem Soc 1966;88:3888-3890.
9. Kunimoto T, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1- piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-5947.
10. Hsiang YH, et al. DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 1989;49:4835-4839.
11. Chen AY, et al. Campthotecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 1991;52:6039-6044.
12. Ohno R, et al. An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990;8:1907-1912.
13. Fukuoka M, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992;10:16-20.
14. Noda K, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346(2):85-91.
15. Bodurka DC, et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 2003;21(2):291-297.
16. Lhomme C, et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1999;17(10):3136-3142.
17. Shimada Y, et al. Phase II study of CPT-11, a new derivative of camptothecin, in metastatic colorectal cancer. J Clin Oncol 1993;11:909-913.
18. Kambe M, et al. A late phase II study of irinothecan (CPT-11) in patients with advanced gastric cancers. Proc Am Soc Clin Oncol 1993(abst 584);12:198.
19. Matsumoto N, Nakano S, Esaki T, Fujishima H, Niho Y. Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removel by 7-ethyl-10 hydroxy-campthotecin in HST-1 human squamous carcinoma cells. Int J Cancer 1995;62:70.
20. Matsumoto N, et al. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10 hydroxy-campthotecin in an HST-1 human squamous carcinoma cell. Anticancer Res 1995;15:405.
21. Shirao K, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997;15:921-927.
22. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma - 2nd English Edition - response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer 2001;4:1-8.
23. Rothenberg ML, et al. Phase I and pharmacokinetic tail of weekly CPT-11. J Clin Oncol 1993;11:2194-2204.
24. Abigerges D, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995;13:210-221.
25. Catimel G, et al. Phase I and pharmacologic study of irinotecan (CPT-11) administered daily for three consequtive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995;6:133-140.
26. Ohe Y, et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992;84:972-974.
27. Kohne CH, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 2003;89(6):997-1001.
28. Boku N, et al. Phase II study of combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-323.
29. Ajani JA, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma results of a phase II study. Cancer 2002;94(3):641-646.
30. Yoshida M, et al. Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice. Gastric Cancer 2001;4:144-149.